AstraZeneca ($AZN) has been doing everything it can to move up in the frenetic race to develop new checkpoint inhibitors, and it made its best effort with a preliminary snapshot of positive results for a combination of the anti-PD-L1 MEDI4736 and tremelimumab in lung cancer. Up to now 18 patients have been treated and 5--or 28%--had responded with signs of tumor shrinkage, according to a Reuters report from Madrid. "It looks very, very promising," Scott Antonia of the Moffitt Cancer Center in Florida told Ben Hirschler. It also looks like very, very early data."
-Fierce Biotech.
And:-
Not to forget GSK. Probably the outsider as they don't have a CI, and are already tied up with Adaptimmune.
However.....
"The group has at least a dozen oncology assets in clinical development, most at an early stage but including some promising new approaches that Axel Hoos, its head of oncology R&D, believes could be at the forefront of the next generation of cancer therapies."
"Mr Hoos says GSK is only interested in “transformational” cancer drugs that are either first-in-class or highly differentiated from rivals. Many observers will remain sceptical until further clinical data arrives but at least GSK has put itself back on the oncology map"
Market Data 
Markets 
AI
